<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876301</url>
  </required_header>
  <id_info>
    <org_study_id>SPK-8011-301</org_study_id>
    <nct_id>NCT03876301</nct_id>
  </id_info>
  <brief_title>Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants</brief_title>
  <official_title>A Multi-Center, Observational Study in Males With Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, observational study is to establish a dataset on the frequency&#xD;
      of bleeding events, as well as other characteristics of bleeding events and FVIII infusions,&#xD;
      in patients with clinically severe hemophilia A receiving prophylactic FVIII replacement&#xD;
      therapy as standard of care. The data collected from this study may assist in providing&#xD;
      baseline information for comparison to the Spark's investigational hemophilia A gene therapy&#xD;
      in future Phase 3 studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeding events, annualized</measure>
    <time_frame>12 months</time_frame>
    <description>Annualized bleeding rate (ABR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose and total FVIIII consumption</measure>
    <time_frame>12 months</time_frame>
    <description>Total FVIII replacement therapy consumption and the corresponding dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized number of infusions (AIR)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of reported infusions over the study period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <condition>Blood Coagulation Disorders, Inherited</condition>
  <condition>Coagulation Protein Disorders</condition>
  <condition>Hemophilia A</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Hemorrhagic Disorders</condition>
  <condition>Factor VIII Deficiency</condition>
  <arm_group>
    <arm_group_label>Observational Cohort</arm_group_label>
    <description>Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care FVIII Replacement therapy</intervention_name>
    <description>There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.</description>
    <arm_group_label>Observational Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males with clinically severe hemophilia A (i.e., ≤2% IU/dL FVIII activity level), who&#xD;
        meet eligibility criteria for neutralizing antibody (NAb) to AAV-Spark200.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide written informed consent.&#xD;
&#xD;
          2. Males ≥18 years of age.&#xD;
&#xD;
          3. Clinically severe hemophilia A&#xD;
&#xD;
          4. Previous exposure to FVIII therapy&#xD;
&#xD;
          5. No prior history of hypersensitivity or anaphylaxis associated with an FVIII or&#xD;
             intravenous immunoglobulin administration.&#xD;
&#xD;
          6. No measurable inhibitor against FVIII&#xD;
&#xD;
          7. Willing to participate and receive treatment in a future Spark hemophilia A gene&#xD;
             therapy study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented active hepatitis B or C within the past 12 months of Screening&#xD;
&#xD;
          2. Currently on antiviral therapy to treat hepatitis B or C;&#xD;
&#xD;
          3. Documented significant liver disease within the past 6 months of Screening&#xD;
&#xD;
          4. Have serological evidence of HIV-1 or HIV-2&#xD;
&#xD;
          5. Anti-AAV-Spark 200 neutralizing titers ≥1:1&#xD;
&#xD;
          6. Previously received SPK-8011;&#xD;
&#xD;
          7. Previously dosed with any investigational or approved gene therapy product at any time&#xD;
             or treated with an investigational drug within the last 12 weeks;&#xD;
&#xD;
          8. Planned surgical procedure in the next 12 months requiring FVIII prophylactic&#xD;
             treatment.&#xD;
&#xD;
          9. Any history of chronic infection or other chronic disease, concurrent clinically&#xD;
             significant major disease (such as liver abnormalities or type I diabetes) including&#xD;
             active malignancy, except for non-melanoma skin cancer, any other condition or any&#xD;
             other unspecified reasons that, in opinion of the Investigator or Sponsor, makes the&#xD;
             participant unsuitable for participation and dosing in a future clinical study for&#xD;
             Spark's hemophilia A gene therapy.&#xD;
&#xD;
         10. Unable or unwilling to comply with the schedule of visits and/or study assessments&#xD;
             described in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Genetically male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Spencer K Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mississippi Center for Advanced Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloodworks Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Austrailia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hematology/St. Paul's Hosptial</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V621Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University / Royal Prince Alfred Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII</keyword>
  <keyword>Factor VIII Protein</keyword>
  <keyword>Recombinant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Coagulation Protein Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders, Inherited</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

